step 9 semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Happy to share the publication – Once-Weekly Semaglutide in Adults with

In the component of primary outcome, persistent 50% eGFR decline from baseline was significantly reduced in semaglutide group (HR 0.73, 95% CI 0.590.89)

In contrast, direct central mechanisms including PI3K/Akt-mediated neuroprotection, BDNF upregulation, and enhanced autophagy are primarily supported by preclinical data obtained at drug concentrations substantially higher than those achievable in the human brain at therapeutic doses

Your prescribing physician should order follow-up labs at regular intervals and adjust your protocol based on results and your subjective response to therapy

doi: 10.1089/jmf.2013.2751 258 PamunuwaGKarunaratneDNWaisundaraVY